ULBP2 in cancer: ligand state, immune regulation, and therapeutic targeting
Abstract
UL16-binding protein 2 (ULBP2) is a stress-inducible NKG2D ligand whose expression has been linked to both tumor recognition and poor clinical outcomes. These observations are difficult to interpret from expression measurements alone. We review evidence on ULBP2 regulation, immune function, and therapeutic targeting, distinguishing surface ligand from intracellular and soluble protein. Shedding can weaken tumor-cell recognition by removing surface ULBP2, whereas the direct suppressive effects of soluble ULBP2 vary across experimental systems. Persistent surface expression also reduced NKG2D expression and cytotoxicity in an engineered murine model. Recent tumor-type-specific perturbation studies implicate ULBP2 in MAPK-associated malignant phenotypes, TGF-β-linked fibroblast and extracellular-matrix responses, and radioresistance. These findings extend the functional landscape of ULBP2 beyond immune recognition, although direct receptor-proximal mechanisms remain unresolved. We propose the ULBP2 State Model as a working framework that considers accessible surface abundance, localization, molecular form, and exposure duration alongside the immune-stromal environment and treatment context. Therapeutic approaches include controlling ligand shedding, redirecting effector cells with ULBP2-containing immunoligands, NKG2D-based cellular therapies, and direct ULBP2-specific chimeric antigen receptor (CAR) targeting. A central implication is that ULBP2 associated with impaired endogenous immunity may still provide an antigen for engineered cellular therapies. Together, these findings support a shift from expression-based to state-resolved interpretation of ULBP2. The ULBP2 State Model links ligand biology with immune function and therapeutic vulnerability, providing a framework for understanding how the same molecule can mediate immune recognition, immune adaptation, and therapeutic targeting in different contexts.
Related
- VISTA as an emerging immune checkpoint in cervical cancer: spatial immune regulation, myeloid–T Cell crosstalk, and therapeutic opportunities
- Macrophage functional plasticity in periodontitis: microenvironmental regulation, disease progression, and therapeutic targeting
- Neural regulation of tumor immune evasion and immunotherapy resistance: mechanisms and therapeutic strategies
- From CAF heterogeneity to immune modulation and therapeutic targeting: a subtype-based framework
- Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting
BibTeX
@article{liu2026ulbp2,
title = {{ULBP2 in cancer: ligand state, immune regulation, and therapeutic targeting}},
author = {Jiarun Liu and Xiaohuan Wang and Junlin Chen and Xinyu Wang and Xuning Wang and Yongqi Shan},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.2006402},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2006402},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - ULBP2 in cancer: ligand state, immune regulation, and therapeutic targeting
AU - Jiarun Liu
AU - Xiaohuan Wang
AU - Junlin Chen
AU - Xinyu Wang
AU - Xuning Wang
AU - Yongqi Shan
PY - 2026
DA - 2026/11/04
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.2006402
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2006402
AB - UL16-binding protein 2 (ULBP2) is a stress-inducible NKG2D ligand whose expression has been linked to both tumor recognition and poor clinical outcomes. These observations are difficult to interpret from expression measurements alone. We review evidence on ULBP2 regulation, immune function, and therapeutic targeting, distinguishing surface ligand from intracellular and soluble protein. Shedding can weaken tumor-cell recognition by removing surface ULBP2, whereas the direct suppressive effects of soluble ULBP2 vary across experimental systems. Persistent surface expression also reduced NKG2D expression and cytotoxicity in an engineered murine model. Recent tumor-type-specific perturbation studies implicate ULBP2 in MAPK-associated malignant phenotypes, TGF-β-linked fibroblast and extracellular-matrix responses, and radioresistance. These findings extend the functional landscape of ULBP2 beyond immune recognition, although direct receptor-proximal mechanisms remain unresolved. We propose the ULBP2 State Model as a working framework that considers accessible surface abundance, localization, molecular form, and exposure duration alongside the immune-stromal environment and treatment context. Therapeutic approaches include controlling ligand shedding, redirecting effector cells with ULBP2-containing immunoligands, NKG2D-based cellular therapies, and direct ULBP2-specific chimeric antigen receptor (CAR) targeting. A central implication is that ULBP2 associated with impaired endogenous immunity may still provide an antigen for engineered cellular therapies. Together, these findings support a shift from expression-based to state-resolved interpretation of ULBP2. The ULBP2 State Model links ligand biology with immune function and therapeutic vulnerability, providing a framework for understanding how the same molecule can mediate immune recognition, immune adaptation, and therapeutic targeting in different contexts.
SN - 1664-3224
ER -